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Background: The proteoglycan biglycan (BGN) is involved in collagen fibril assembly and its fragmentation is likely
to be associated with collagen turnover during the pathogenesis of diseases which involve dysregulated
extracellular matrix remodeling (ECMR), such as rheumatoid arthritis (RA) and liver fibrosis. The scope of the present
study was to develop a novel enzyme-linked immunosorbent assay (ELISA) for the measurement of a MMP-9 and
MMP-12-generated biglycan neo-epitope and to test its biological validity in a rat model of RA and in two rat
models of liver fibrosis, chosen as models of ECMR.
Results: Biglycan was cleaved in vitro by MMP-9 and −12 and the 3440YWEVQPATFR0353 peptide (BGM) was chosen
as a potential neo-epitope. A technically sound competitive ELISA for the measurement of BGM was generated and
the assay was validated in a bovine cartilage explant culture (BEX), in a collagen induced model of rheumatoid
arthritis (CIA) and in two different rat models of liver fibrosis: the carbon tetrachloride (CCL4)-induced fibrosis
model, and the bile duct ligation (BDL) model. Significant elevation in serum BGM was found in CIA rats compared
to controls, in rats treated with CCL4 for 16 weeks and 20 weeks compared to the control groups as well as in all
groups of rats subject to BDL compared with sham operated groups. Furthermore, there was a significant
correlation of serum BGM levels with the extent of liver fibrosis determined by the Sirius red staining of liver
sections in the CCL4 model.
Conclusion: We demonstrated that the specific tissue remodeling product of MMPs-degraded biglycan, namely the
neo-epitope BGM, is correlated with pathological ECMR. This assay represents both a novel marker of ECM turnover
and a potential new tool to elucidate biglycan role during the pathological processes associated with ECMR.
Keywords: Biglycan, Biochemical markers, Extracellular matrix remodeling, Matrix-metalloproteinase, Neo-epitopesBackground
Tightly controlled extracellular matrix (ECM) remodeling
is essential for development, wound healing and normal
organ homeostasis. However, sustained dysregulation of
this remodeling, leading to excessive matrix deposition,
can contribute to the onset of life-threatening patho-
logical conditions [1]. The ECM proteins are key players
in tissue failure and can become the driving force of the
pathogenesis of fibrotic diseases, tumor progression and
metastasis [2].* Correspondence: fge@nordicbioscience.com
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reproduction in any medium, provided the orBiglycan (BGN) is a secreted proteoglycan that belongs
to the family of small leucine-rich proteoglycans (SLRPs),
consisting of a core protein and one or two chondroitin
sulfate/dermatan chain(s) bound covalently through a
tetrasaccharide bridge to a serine residue. Together with
decorin, fibromodulin and lumican, biglycan is a key regu-
lator of lateral assembly of collagen fibers. Biglycan has
been shown to specifically interact with type VI collagen
by binding the N-terminal region of the triple helix [3].
Deficiency of one or more SLRPs, as well as targeted dis-
ruption of the biglycan gene, leads to abnormal collagen
fiber diameters and disturbed lateral association of fibers
[4]. Biglycan is thought to also have a role in fibrogenesisral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protein contains leucine-rich repeats that facilitate protein-
protein interactions: this proteoglycan is in fact able to
bind to the membrane-bound proteoglycan dystroglycan
and to a wide variety of proteins, being involved in, for
instance, cell signal transduction during cell growth and
differentiation and in regulating cytokine activity due to
its capacity to bind TGF-β and TNF-α [4]. TGF-β1 has
been identified as the most pro-fibrotic cytokine, being
responsible, for instance, for hepatic stellate cell trans-
differentiation into myofibroblast in the first stages of
liver fibrosis [6]. By binding to TGF-β1, biglycan is able
to inhibit its bioactivity in vitro [7]. Moreover it has been
demonstrated that the activity of TGF-β1 is strictly re-
lated to the presence of biglycan also in vivo, as biglycan-
deficient mice have shown elevated levels of both total
and bioactive TGF-β1 in plasma [8].
Endopeptidases like matrix metalloproteinases (MMPs)
play a key role in the degradation of extracellular macro-
molecules such as collagens and proteoglycans. In the
fibrous tissue many MMPs, including MMP-9 and MMP-
12, are highly regulated and are responsible for the exces-
sive proteolytic activity [9-11]. The fragmentation of ECM
proteins by specific proteases like MMPs, generates small
peptides, the so-called neo-epitopes, which may be used
as biochemical markers.
The aim of the present study was to identify a patho-
logical neo-epitope originated by MMP-9 and MMP-12
-mediated biglycan degradation that potentially is a sero-
logical marker for pathological extracellular matrix re-
modeling (ECMR). Animal models of liver fibrosis were
chosen to investigate the relation between this novel
biglycan marker and ECMR in fibrosis-related diseases.
Furthermore the levels of MMP-degraded biglycan were
assessed in an ex vivo cartilage explant model, as well as
in a rat model of collagen-induced arthritis to test the
biological validity of the assay.Figure 1 Cleavage originated peptides and selected BGM. (a) Selection
(b) Position of the selected peptide BGM in the biglycan sequence.Results
Selection of neo-epitope by mass spectrometry
Purified bovine biglycan was cleaved with a variety of
MMPs including MMP-9 and −12, and 120 unique
biglycan peptides were identified in the cleaved material.
Some of the peptides were generated by both proteases,
while others were unique for each protease. The diges-
tion of biglycan over time revealed a time-dependant
peptide generation, with some peptides being generated
within the first few hours and others after two or three
days (data not shown). The length of protease-generated
peptides of biglycan was between 10 and 50 amino acids.
All peptides were tested for homology and cross-
reactivity to other human proteins and across species.
Antibodies were generated against sixteen neo-epitope
sequences (the non-selected fifteen sequences are shown
in Figure 1a), and based on the reactivity against the se-
lection peptide, the specificity for the cleaved biglycan,
and the reactivity against native material (human and rat
serum), one of the antibodies recognizing one of the
peptides identified by LC-MS/MS was selected for as-
say development. The neo-epitope ⇓344YWEVQPATFR353
(BGM) (Figure 1b) was generated by MMP-9 and −12,
MMP-12 generating the largest quantities of this peptide
(Figure 2b). Furthermore, BGM is one of the peptides
generated during the early phases of in vitro digestion,
whereas the largest quantity of the peptide released is
seen after 72 hours. The BGM peptide was shown to be
unique to biglycan with 100% homology across different
species (Homo sapiens, Mus musculus, Rattus norvegicus,
Canis lupus familiaris, Equus caballus, Bos Taurus,
Ovis aries).
Selection of monoclonal antibody for assay development
From the mouse immunized with the selected sequence,
YWEVQPATFR-GGC-OVA, the clone NB202-7-9D6 was
selected for assay development due to the highest andof peptides generated from MMP-9 and −12 cleavages over time.
Figure 2 Technical performance of BGM ELISA. (a) Standard peptide, elongated peptide and non-sense peptide and coater in the BGM
competitive ELISA setting (b) BGM measurement for in vitro MMP-9 and MMP-12-degraded biglycan (BGN/MMP9, BGN/MMP12) and for intact
biglycan (BGN).
Table 1 Technical evaluation of the BGM competitive
ELISA
Technical validation step BGM ELISA
Target MMP-9 and −12 degradation
of biglycan
Lower limit of detection (LDL) 1.54 ng/mL
Dilution recovery of human serum 100% (1:2), 103% (1:4)
Dilution recovery of human plasma 97% (1:2), 99% (1:4)
Dilution recovery of rat serum 107% (1:2), 102% (1:4)
Dilution recovery of rat plasma 89% (1:2)
Dilution recovery of mouse serum 105% (1:2)
Dilution recovery of mouse plasma 97% (1:2)
Intra-assay variation 10%
Inter-assay variation 15%
Percentage dilution recovery and percentage intra/inter variation are indicated
as mean values of different samples diluted 1:2 and 1:4 and as mean variation
between ten individual determinations of human samples, respectively.
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biglycan degraded in vitro by MMP-9 and −12. The BGM
neo-epitope is located only 25 amino acids from the C-
terminus, just outside the leucine-rich-repeat area, there-
fore the peptides recognized by the BGM antibody are
expected to be from 6 to 25 amino acids long (Figure 1b).
Technical performance of the BGM assay
The competitive ELISA assay BGM was developed using
the NB202-7-9D6 clone and tested for reactivity to the
BGM fragment ⇓YWEVQPATFR. Neither the elongated
peptide (PYWEVQPATFR) nor the non-sense peptide
(NNQIDHIDEK) were able to displace the signal, indi-
cating the antibody-antigen reaction was specific to the
neo-epitope of the selected biglycan cleavage product.
Moreover, no reactivity was shown using a non-sense
coater (Biotin-K-NNQIDHIDEK) (Figure 2a). Native,
uncleaved biglycan was also incapable of displacing the
signal, while only MMPs-cleaved biglycan peptides could
inhibit the signal in the assay. Different proteases had dif-
ferent efficiency in cleaving biglycan and generating BGM
(Figure 2b). The assay performance is summarized in
Table 1. The calculated lower detection limit (LDL) was
1.54 ng/mL. The intra-assay variability was 10% and the
inter-assay variability was on average 15%.
BGM is produced by bovine cartilage explants ex vivo
To investigate the generation of this unique fragment,
we performed an ex vivo experiment on bovine cartilage
explants (BEX) cultured for 17 days in the presence of
TNF-α and oncostatin (T+O) or in four other solutions.
The addition of catabolic supplements has previously
been shown to potently induce time-dependent cartilage
degradation by aggrecanases and MMPs [5]. At early
time points (three and eight days of culture) no differ-
ence in the release of BGM was seen between any of the
five culture groups. At the end of culturing period (day
17) a more than two-fold increase in peptide release was
observed in the T+O culture group compared to non-stimulated cultures (Figure 3). The selective MMP in-
hibitor, GM6001, added to the TNF-α and oncostatin
culture, abrogated the increased levels of BGM, demon-
strating a MMP-dependant release of the neo-epitope.
The addition of T+O in presence of the cysteine prote-
ase inhibitor E64 significantly (P < 0.005) augmented the
release of the BGM, as compared to T+O alone.
CIA model
Serum BGM was investigated at day 22 in a CIA rat
model of RA, following previous results that showed
high levels of collagen degradation at this time point
[12]. Results are presented in Figure 4: serum BGM
levels are significantly more elevated in CIA animals
compared to controls (sham: 10 ng/mL, CIA: 20 ng/mL,
P < 0.0001).
Sirius red staining of livers in rat models of liver fibrosis
Sirius red staining of livers of CCL4 rats was performed
for all animal groups, and the results are presented in
Figure 3 BGM release from ex vivo cultures of bovine explants (BEX), measured at day 3 and 17 of culturing on five replicates.
w/o = cultures without any stimulation; MI = metabolically inactive cultures by the treatment with liquid nitrogen; T+O = catabolic cytokine
stimulation with TNF-α (20 ng/mL) and oncostatin (10 ng/mL); T+O+GM6001 = catabolic cytokines TNF-α (20 ng/mL) and oncostatin (10 ng/mL)
supplemented with selective MMP inhibitor GM6001; T+O+E64 = catabolic cytokines TNF-α (20 ng/mL) and oncostatin (10 ng/mL) supplemented
with selective cysteine protease inhibitor E64. (*** P < 0.001).
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weeks of CCL4 treatment, peaks at 16 weeks of treat-
ment, and seems to regress to 12-week levels at 20 weeks
of treatment.Figure 4 Mean circulating serum BGM levels in a collagen-induced
arthritis (CIA) rat model of rheumatoid arthritis measured at day
22. Data are shown as mean ± standard error of the mean (SEM)
(*** P < 0.001).BGM for detection of liver fibrosis in rat CCL4 and
BDL model
CCL4 model
After eight weeks, no significant difference was seen in
the serum BGM in the groups of 52 male Wistar rats
treated bi-weekly with inhalable CCL4 and phenobar-
bital in drinking water, and the 28 control rats receiving
phenobarbital only (Figure 6a). By 12, 16 and 20 weeks,
there was an increase in serum BGM levels in CCL4-
treated rats, and this increase was found to be significant
compared with control rats at 16 weeks (controls: 30 ng/
mL, CCL4: 50 ng/mL, P = 0.0013) and 20 weeks (con-
trols: 25 ng/mL, CCL4: 47 ng/mL, P = 0.019). We found
no significant difference in serum levels of control rats
during the study period. Correlations of the levels of
serum BGM with the percentage of fibrotic tissue deter-
mined by Sirius red, indicating the extent of liver fibro-
sis, are presented in Figure 6c and 6d. As illustrated, we
found a significant correlation (r = 0.77, P < 0.0001) be-
tween levels of serum BGM of CCL4 animals and the ex-
tent of their fibrosis. No significant correlation was found
in control animals (r = −0.28, P = ns). By further data
analysis all animals were divided into quartiles according
to the extent of fibrosis in the tissue as determined by Sir-
ius red staining, and stratified according to the level of
serum BGM (Figure 6b). These data analysis showed that
the animals with the highest levels of serum BGM showed
the most extensive fibrosis.BDL model
Serum BGM levels increased significantly in all BDL groups
compared with sham groups (group 1: sham 27 ng/mL,
BDL 56 ng/mL, P < 0.01; group 2: sham 25 ng/mL, BDL
47 ng/mL, P < 0.001; group 3: sham 12 ng/mL, BDL 35
ng/mL, P < 0.001; group 4: sham 14 ng/mL, BDL 37 ng/
mL, P < 0.05) (Figure 7). The serum BGM levels in BDL
animals were significantly elevated at termination com-
pared to baseline at all time points except at week 4 (week
1 baseline: 24 ng/mL, termination: 56 ng/mL, P < 0.01,
week 2 baseline: 21 ng/mL, termination: 47 ng/mL,
P < 0.001, week 3 baseline: 24 ng/mL, termination: 35 ng/
mL, P < 0,025, week 4 baseline: 23 ng/mL, termination:
37 ng/mL, P = 0,07). An increased trend was observed in
Figure 5 Absolute values of Sirius red quantification, indicated
as % collagen in CCL4-treated rats determined at 8, 12, 16, and
20 weeks of treatment. (CCL4-treated animals: n = 13; controls:
n = 7 for each group). The bars indicate mean ± standard error of
the mean (SEM) (** P < 0.01, *** P < 0.001).
Figure 6 BGM in CCL4 rats. (a) Mean circulating serum BGM levels in car
at 8, 12, 16, and 20 weeks (CCL4−treated animals: n = 13; controls: n = 7 fo
stratified in quartiles according to total collagen content in the liver determ
P < 0.001). Correlation of circulating serum BGM and histological Sirius red qu
rats and (d) controls.
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decreased over time from week 2 to weeks 3 and 4, but
this was not statistically significant.
Discussion
MMP degradation of ECM components generates specific
cleavage fragments, called neo-epitopes. The combination
of a specific protease and a specific ECM protein compo-
nent, namely protein fingerprint, may provide a unique
combination that can be relevant for a certain pathology
and be ascribed to a specific tissue [13]. This class of bio-
markers has proven successful in studies on osteoarthritis
and osteoporosis [14], liver [15,16] and skin fibrosis [17].
Collagen protein fingerprints have already been used to
generate novel neo-epitope markers of ECM remodeling
[18-20], and considering the role of biglycan as collagen
assembly regulator in many tissues, we hypothesized that
biglycan is also remodeled during the same pathological
processes that lead to dysregulated ECM turnover. To val-
idate this hypothesis, we developed an immunological
assay detecting a neo-epitope of biglycan generated by
MMP-9 and MMP-12 cleavage (BGM) in serum, and
measured the levels of this marker in one rat model ofbon tetrachloride (CCL4)-induced rat model of liver fibrosis measured
r each group). (b) Serum BGM levels in all control rats and all CCL4 rats
ined by Sirius red; (ns = non-significant, * P < 0.05, ** P < 0.01, ***
antification determining the extent of liver fibrosis in (c) CCL4-treated
Figure 7 Mean circulating serum BGM levels in BDL and sham operated rats at baseline and at termination at weeks 1, 2, 3, 4. Data are
shown as mean ± standard error of the mean (SEM) (* P < 0.05, ** P < 0.01, *** P < 0.001).
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model pathologies involving disrupted ECM turnover.
Biglycan is abundant in the ECM of many tissues and it
has been shown to be up-regulated, together with MMPs,
in fibrotic livers [21] and in related diseases such as lung,
heart and kidney fibrosis [22-25]. Despite its functions in
collagen assembly and as a signal molecule implicated in
cell adhesion, migration, differentiation and apoptosis,
have been demonstrated in vitro, biglycan biological roles
in vivo have not yet been fully understood [26].
The ECM is a very complex environment, in which
different proteins such as collagens, proteoglycans and
proteases act together to maintain the equilibrium be-
tween ECM degradation and formation. Many proteases,
including MMPs, are involved in the intricate mechan-
ism of fibrogenesis in vivo, each of them contributing to
the proteolysis of different ECM proteins. The in vivo
interplay that occurs between different types of proteases
can be successfully simulated by ex vivo models [5]. In
this study, we performed an ex vivo experiment on bo-
vine cartilage explant cultures using the developed assay
to measure the levels of BGM generated in the cultures.
Cartilage degradation in these cultures is known to fol-
low a time-dependent path, in which firstly aggrecanase
(ADAMTS), and later MMP activity is responsible for
the catabolic destruction of the cultures [27,28]. Bovine
cultures stimulated with T+O released the highest quan-
tities of the BGM neo-epitope during the MMP induc-
tion period, but this release was completely abrogated by
the addition of the specific MMP inhibitor, GM6001,
demonstrating that the generation of BGM is MMP-
dependent. Interestingly, in the presence of T+O and a
cysteine protease inhibitor, we found an increase rather
than a decrease in BGM levels. This observation suggestscompensatory or feedback mechanisms are part of a com-
plex interplay between the proteases in vivo. We have
previously demonstrated that there is an increase in
MMP-9 activity in the absence of the cysteine protease
Cathepsin K (CatK) in CatK null-mutation mice [12]. This
suggests that caution should be directed to therapies di-
rected at the inhibition of protease activity due to the po-
tential for resulting compensatory mechanisms.
Following the results in the cartilage model, we mea-
sured the serum levels of BGM in an animal model of RA,
an autoimmune disease which causes chronic inflamma-
tion leading to ECMR in the synovial joints. The forma-
tion and degradation profile of different types of collagen
has previously been studied in the CIA model, showing an
increase in collagen degradation neo-epitope levels in
serum with the progression of the disease [29]. Consider-
ing the close association of biglycan with collagen, we
evaluated the potential of BGM as a marker for ECMR in
this model. The results show a good separation between
healthy and diseased animals in the levels of BGM in the
serum, suggesting that this proteoglycan could also be im-
portant in the development of the pathology. To further
confirm the relationship of BGM with ECMR, two animal
models of liver fibrosis, the CCL4-treated rats and the
BDL rats, were investigated to examine the levels of the
biglycan neo-epitope as well as its potential relation to fi-
brosis. Serum BGM levels were significantly correlated
with the extent of liver fibrosis judged by histological Sir-
ius red quantification in CCL4-treated rats. No correlation
was observed between Sirius red determination of liver fi-
brosis extent and levels of BGM in control rats. In the
CCL4 model of liver fibrosis, serum BGM was elevated
after 16 and 20 weeks of treatment compared with con-
trols and these data are in agreement with the literature
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fibrosis [21], where MMP levels are elevated and unbal-
anced during fibrogenesis [30]. This pattern is very similar
to that of other ECM degradation markers in this model,
as shown by means of Z-score plots in the paper by
Leeming et al. [31]. The findings obtained in the CCL4
model were confirmed in the BDL model, where the levels
of serum BGM were elevated to a larger extent in BDL
rats compared to sham-operated rats at all time points.
However this model shows a different expression pattern
compared to the CCL4 model: after an initial peak of
serum BGM in BDL operated animals one week after the
treatment, there is a non-statistically significant trend of
decreasing marker levels at week 4. These results however,
are not surprising, as the two rodent models represent dif-
ferent types of human fibrosis. Bile duct ligation (BDL)
rats are models of chronic liver inflammation similar to
what has been observed in human cholestatic liver disease.
Carbon tetrachloride (CCL4) treatment on the other hand
causes acute liver damage, providing a model resembling
the human condition of alcoholic steatohepatitis with the
consequent fibrosis and cirrhosis [30,32]. Our working hy-
pothesis is that BGM is a marker of fibrosis activity, able
to reflect the levels of ECMR activity and the overall re-
modeling that occurs in an organ. The remodeling out-
come can, in turn, depend on the organ and the insult,
which may vary according to the nature of the treatment
and of the organ system that is affected.
Conclusions
In this work, we have developed the first assay to meas-
ure a pathologically relevant fragment of biglycan in bio-
logical fluids, using a specific monoclonal antibody for
the detection of BGM, a biglycan fragment derived from
MMP-9 and MMP-12 activity, in human, rat and mouse
serum. We have demonstrated that this serum marker is
elevated in a rat model of RA and in two rat models of
liver fibrosis and it is highly correlated with the extent of
fibrosis, suggesting serum BGM is a relevant biomarker
for ECMR. This assay enables the analysis of biglycan
degradation in both animal studies and potentially in
clinical settings. The use of this assay in clinical studies
of diseases involving ECM remodeling might be useful
to elucidate the role that biglycan exerts not only in the
complex tissue environment during the pathological pro-
cesses that cause RA and fibrosis, but also in other tis-
sues where biglycan is expressed, such as muscle, bone,
teeth and tendon.
Methods
Materials
All chemicals, enzymes and cell culture reagents were
purchased from Sigma-Aldrich (Copenhagen, Denmark),
or VWR (Herlev, Denmark), if not otherwise stated. TheELISA plates, pre-coated with streptavidin (Nunc clear
96-well plates), were purchased from Roche Diagnostics
(Mannheim, Germany). Immunogens, standard and coat-
ing peptides were purchased from the Chinese Peptide
Company (Beijing, China) and from American Peptide
(Sunny Valley, CA, USA).
In vitro peptide generation
The BGM neo-epitope was identified by in vitro deg-
radation of bovine articular cartilage purified biglycan
(Sigma-Aldrich, Copenhagen, Denmark) by MMP-9
and −12. The purified biglycan had been filtered to re-
move proteins below 10,000 kDa (Microcon Ultracel YM-
10, catalog number. 42407, Millipore, Billerica, MA, USA)
and had not been de-glycosylated prior to MMP diges-
tion. The buffer used for the MMP cleavage of biglycan (1
mg/mL) consisted of 100 mM Tris–HCl, 100 mM NaCl,
10 mM CaCl2 and 2 mM ZnAc, at pH 8.0. The cleavage
fragments were obtained after 72 hours of incubation with
each protease. As a control biglycan (1 mg/mL) was in-
cubated with MMP-buffer. The cleavages were stopped
by 5 mM EDTA and verified by SDS-PAGE.
Peptide identification and antibody generation
After the in vitro cleavage, peptides of biglycan were iden-
tified using liquid chromatography coupled to electrospray
ionization (ESI) tandem mass spectrometry (LC-MS/MS)
as previously described [15]. To identify peptides, MS and
MS/MS data were searched against a biglycan (FASTA)
protein database using the Mascot 2.2 (Matrix Science,
Boston, MA, USA) software with ESI-QUAD-TOF set-
tings and carbamidomethyl (C), oxidation of methionine
(M), oxidation of lysine (K) and oxidation of proline (P) as
variable modifications. The first six amino acids of each
free end of the protease-generated peptide sequences
identified by MS were regarded as a neo-epitope gener-
ated by the specific protease.
All MMP-9 and −12 generated neo-epitopes were ana-
lyzed for distance to other cleavage sites and then blasted
for protein and species homology using the NPS@: net-
work protein sequence analysis [33]. Among all the differ-
ent neo-epitopes, the sequence 344YWEVQPATFR353 was
chosen according to the mentioned criteria. A monoclonal
antibody targeted against the N-terminal part of the se-
lected peptide was generated as previously described [20].
BGM ELISA development
A competitive ELISA for the biglycan selected neo-epitope
BGM was developed as follows: a 96-well streptavidin-
coated plate was coated with 2.5 ng/mL biotinylated syn-
thetic peptide YWEVQPATFR-K-Biotin dissolved in PBS
buffer (2 mM KH2PO4, 9 mM Na2HPO4, 2H2O, 3 mM
KCl, 137 mM NaCl, pH 7.4) and incubated for 30 min at
20°C by constant shaking at 300 rpm. 20 μL of peptide
Genovese et al. Fibrogenesis & Tissue Repair 2013, 6:9 Page 8 of 10
http://www.fibrogenesis.com/content/6/1/9calibrator prepared by two-fold pre-dilution of the stand-
ard peptide (YWEVQPATFR) starting from 250 ng/mL or
sample dissolved in assay buffer (2 mM KH2PO4, 9 mM
Na2HPO4, 2H2O, 3 mM KCl, 34 mM NaCl, 5% Osteocalcin
EIA Puf-Liq (Roche Diagnostics Deutschland GmbH) pH
7.4) were added to appropriate wells, followed by 100 μL of
40 ng/mL peroxidase-labeled NB202-7 9D6 antibody and
incubated for one hour at 20°C by constant shaking at 300
rpm. Finally, 100 μL of tetramethylbenzidine (TMB) (cata-
log number 438OH; Kem-En-Tec, Copenhagen, Denmark)
were added, and the plate was incubated for 15 minutes at
20°C in the dark and shaken at 300 rpm. After each incu-
bation step, the plate was washed five times in washing
buffer (20 mM Tris, 50 mM NaCl, pH 7.2). The TMB re-
action was stopped by adding 100 μL of stopping solution
(1% HCl) and the colorimetric reaction was measured at
450 nm with reference at 650 nm on a standard labora-
tory plate reader. Data were acquired with the SoftMax
Pro v5.0 (Molecular devices, LLC, Sunnyvale, CA, USA)
program.
Technical evaluation of BGM assay
Technical assay validation was performed according to
international guidelines of assay development. Briefly,
linearity was calculated as a low, medium or high per-
centage of recovery of the 100% sample from two-fold
dilutions of quality control (QC) human serum and from
rat serum. The lower limit of detection (LDL) was deter-
mined from 21 zero samples (buffer only) and calculated
as the mean + 3 x standard deviation. Percentage dilu-
tion recovery was calculated as the mean of five human
serum and five human plasma samples, four rat serum
and four rat plasma and three mouse serum and three
mouse plasma diluted 1:2 and 1:4. Inter- and intra-assay
variations were calculated as the mean variation between
ten individual determinations of eight QC samples (hu-
man serum) with each run consisting of two replicas of
double determinations of the samples.
ELISA characterization
The developed BGM ELISA was evaluated using 20 μL
of the samples: intact biglycan, biglycan cleaved with
MMP-9, biglycan cleaved with MMP-12, the standard
BGM peptide YWEVQPATFR and the BGM peptide
elongated at the N-terminal end with one amino acid
(PYWEVQPATFR). Specificity was tested using a non-
sense peptide NNQIDHIDEK and a non-sense coater
Biotin-K- NNQIDHIDEK.
Bovine cartilage explant cultures
Bovine cartilage explants (BEX) were harvested by dissecting
the outermost layer of articular cartilage from bovine
knee joints, as previously described [34]. The cartilage
explants (16 ± 4 mg) were placed in 96-well plates andincubated at 37°C, with 5% CO2 and shaken at 50 rpm
under serum-free conditions (n = 5 per condition). Each
explant was cultured in 200 μl of DMEM for seventeen
days, with the medium being changed every three to four
days, under one of the following conditions: 1) Without
catabolic factors (W/O), 2) Metabolically inactivated by li-
quid nitrogen, 3) With the catabolic cytokines oncostatin
M (10 ng/mL) and TNF-α (20 ng/mL), O+T to stimu-
late MMP activity; 4) O+T supplemented by the MMP
inhibitor GM6001 (10 μM); and 5) O+T supplemented
by the cysteine protease inhibitor E64 (50 μM), here
used as a negative control, as the selective cathepsin in-
hibitor should not have an effect on MMP activity.
Each condition was replicated five times. The metabolic
activity (viability) of the articular explants was quantita-
tively measured on the last day in culture, using the
Alamar Blue assay (TREK Diagnostic Systems, LTD. East
Grinstead, West Sussex RH19 1XZ UK) according to the
manufacturer’s instructions (data not shown).
Collagen-induced arthritis (CIA) model
Levels of BGM were measured in a CIA rat model.
Complete details of the study have been previously de-
scribed [29]. The animal experiment protocol was ap-
proved by the local animal ethics committee at Nordic
Bioscience Beijing. The ethical approval number is NBB-
AM-R/2009-01. Briefly, CIA was induced in ten seven-
week old female Lewis rats by immunizing with 450 μl 2
mg/mL porcine type II collagen dissolved in 0.05 M
acetic acid and emulsified 1:1 in incomplete Freund’s
adjuvant on day 0 and 7. Ten Lewis rats, injected only
with 0.05 M acetic acid, were used as control. Every day,
starting from day 8, rats were examined for visual signs
of disease, defined as macroscopic evidence of increase
in paw size. The rats were sacrificed on day 26. Serum
samples were collected throughout the experiment from
overnight fasted animals.
Rat model of CCL4-induced liver fibrosis
Serum BGM levels were measured in a CCL4 inhalation
rat model of liver fibrosis. Complete details of the study
have been previously described [35]. The CCL4 study was
approved by the Ethical Committee of Animal Experi-
mentation of the University of Barcelona (B-NNP-233/09)
and was performed according to the criteria of the In-
vestigation and Ethics Committee of the Hospital Clinic
Universitari (Barcelona, Spain). The study included 52
male Wistar rats treated with CCL4 and 28 male Wistar
control rats (Charles-River, Saint Aubin les Elseuf, France).
Induction of liver fibrosis was performed as previously de-
scribed [36]. Briefly, CCL4 was administered by inhalation
twice weekly and phenobarbital (0.3 g/l) added to the
drinking water. Control rats received phenobarbital only.
Animals were stratified into groups receiving CCL4 or
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CCL4; n = 7 control for each group). Four animals from
the CCL4 groups died during the study. Blood was col-
lected at termination and allowed to stand at room
temperature for 30 minutes to allow clotting, before cen-
trifugation at 3,000 g for 10 minutes. All clot-free liquid
was transferred to new tubes and centrifuged again at
3,000 g for 10 minutes. Samples were stored at −80°C prior
to biomarker assessment. Liver sections (4 μm thick) were
stained in 0.1% Sirius red F3B (Sigma-Aldrich, St. Louis,
MO, USA) in saturated picric acid (Sigma-Aldrich St.
Louis, MO, USA). From each animal analyzed, the amount
of fibrosis was expressed as a percentage of the total liver
area of 36 fields and the average value is presented. Each
field was acquired at 10 x magnification [37].
Rat model of bile duct ligation (BDL) induced liver fibrosis
Serum BGM levels were measured in a rat model of liver
fibrosis induced by bile duct ligation. Complete details
of the study have been previously described [18,35]. The
BDL experiment was approved by the Experimental Ani-
mal Committee of the Danish Ministry of Justice and
was performed according to the European Standard for
Good Clinical Practice (2008/561-1450).
The study included a total of 81 female Sprague–
Dawley rats aged six months. Liver fibrosis was induced
in anaesthetized rats by standard BDL in which the
bile duct was ligated in two places and dissected between
the ligations prior to closing the abdomen. In sham-
operated rats, the abdomen was closed without BDL. The
rats were divided into four groups: group 1 (10 BDL,
8 sham) was sacrificed after one week, group 2 (12 BDL, 8
sham) sacrificed after two weeks, group 3 (13 BDL, 8 sham)
sacrificed after three weeks, and group 4 (14 BDL, 8 sham)
sacrificed after four weeks. During the four weeks, 15 of 81
rats, 14 of them BDL operated, were terminated due to ex-
cessive weight loss.
Statistics
The ELISA standard curve was fitted by the four-parameter
method:
y ¼ A−Dð Þ= 1þ x=Cð Þ∧B þ D; where R > 0:9
Comparison between measurements of biomarkers in
culture supernatants and differences between tertiles were
assessed by one-way ANOVA with Dunnett’s post-test
assuming Gaussian distribution, on accumulated data.
Comparison of two subject groups was made using the
non-parametric Mann–Whitney test, α = 0.05. The corre-
lations coefficient was calculated using the Spearman’s ρ
non-parametric test. GraphPad Prism v.5 (GraphPad Soft-
ware, Inc. La Jolla, CA 92037 USA) was used for drawing
graphs and calculating statistics.Abbreviations
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